BioCardia Announces First Patient Enrollment in Phase 3 CardiAMP HF II Trial.

BioCardia has announced the enrollment of the first patient in its ongoing Phase 3 CardiAMP HF II clinical trial at the University of Wisconsin School of Medicine and Public Health. The trial aims to evaluate the efficacy of CardiAMP cell therapy for ischemic heart failure patients. Dr. Amish Raval, a professor of medicine at UW School of Medicine and Public Health, expressed enthusiasm for the study, citing evidence of benefit for patients despite optimized medical therapy. The trial seeks to provide more evidence for the therapy's potential availability.